Welcome to our dedicated page for COLGATE PALMOLIVE CO SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COLGATE PALMOLIVE CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COLGATE PALMOLIVE CO's regulatory disclosures and financial reporting.
Colgate-Palmolive Company’s Chief Growth Officer reported a small share transaction involving company stock. On 12/03/2025, 156 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share in a transaction coded “F,” which indicates shares were withheld by the company to cover Medicare and income tax obligations tied to previously granted restricted stock units. After this tax withholding, the officer beneficially owns 17,645 shares directly and 5,416 shares indirectly through the issuer’s 401(k) plan trustee. The underlying restricted stock units remain in place, reduced only by the shares used for required tax withholding.
Colgate-Palmolive (CL) reported a routine insider tax-withholding transaction by its Chief Legal Officer and Secretary. On 12/03/2025, the executive had 213 shares of common stock withheld at a price of $78.2 per share, coded as an "F" transaction, which indicates shares were withheld to cover Medicare and income tax obligations on previously granted restricted stock units under the company’s incentive compensation plan.
After this non-open-market transaction, the executive beneficially owns 76,406 shares of Colgate-Palmolive common stock directly and an additional 1,825 shares indirectly through the issuer's 401(k) plan trustee. The filing notes that the restricted stock units themselves continue to be held, reduced only by the amount of shares withheld for taxes.
Colgate-Palmolive Company (CL) reported an insider stock transaction by its Chief Human Resources Officer. On 11/21/2025, the officer sold 1,237 shares of Colgate-Palmolive common stock at a price of $80.89 per share. After this sale, the officer beneficially owned 13,751 shares directly and 8,058 shares indirectly through the issuer's 401(k) plan trustee. The filing was made on a Form 4, which discloses changes in insider ownership.
Colgate-Palmolive Company announced the issuance and sale of €600,000,000 aggregate principal amount of its 3.250% Senior Notes due 2035. The company entered into an underwriting agreement on November 3, 2025 with Barclays Bank PLC and Banco Bilbao Vizcaya Argentaria, S.A., acting as representatives of the underwriters.
The notes were offered under Colgate-Palmolive’s automatic shelf registration statement on Form S-3 (File No. 333-275201), with a Prospectus Supplement dated November 3, 2025 and filed November 5, 2025. The notes were issued on November 10, 2025 under the existing Indenture dated November 15, 1992 with The Bank of New York Mellon as trustee. The underwriting agreement, the Indenture, and the form of the notes were filed as exhibits.
Colgate-Palmolive reported Q3 2025 results with net sales of $5,131 and diluted EPS of $0.91. Net income attributable to the company was $735. For the first nine months, net sales were $15,152 and diluted EPS reached $2.67, up from $2.61 a year ago.
The company completed the acquisition of Care TopCo Pty Ltd (Prime100) for AU $471 (approximately $301) on April 30, 2025, expanding Hill’s into fresh pet food in Australia. It also announced a three‑year Strategic Growth and Productivity Program with estimated cumulative pre‑tax charges between $200 and $300, with substantially all charges expected by December 31, 2028.
In the quarter, parties entered into a settlement agreement to resolve an ERISA lawsuit for $332, which received preliminary court approval in October 2025; a final approval hearing is scheduled for January 2026. Nine‑month cash from operations was $2,745; financing included dividends of $1,300 and treasury share purchases of $804. Shares outstanding were 806,064,942 as of September 30, 2025.
Colgate-Palmolive (CL) filed an 8-K stating it furnished a press release announcing earnings for the quarter ended September 30, 2025, and outlined expected costs for a new three-year Strategic Growth and Productivity Program.
The program is estimated to result in cumulative pre-tax charges of $200 to $300 million. The Company expects 65% to 75% to be employee-related costs (severance and other termination benefits) and 25% to 35% to be asset-related and other charges (accelerated depreciation, asset write-offs, contract termination and other exit costs). It estimates 75% to 85% of these charges will require cash expenditures, with substantially all charges incurred by December 31, 2028. The Company indicates the charges will relate to initiatives across regions and businesses: North America (15% to 20%), Latin America (15% to 20%), Europe (10% to 15%), Asia Pacific (10% to 15%), Africa/Eurasia (5% to 10%), Hill’s Pet Nutrition (10% to 15%), and Corporate (10% to 15%).
Brian Newman, a director of Colgate-Palmolive Co. (CL), reported a non-derivative acquisition of 228 shares of common stock on 10/01/2025 at a price of $82.13 per share. Following the transaction he directly beneficially owns 5,065 shares and indirectly holds 36 shares through a family trust. The filing identifies the purchase code A(1), and the explanation states this represents a portion of the annual cash retainer deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Lorrie M. Norrington, a director of Colgate-Palmolive Company (CL), reported a transaction dated 10/01/2025 in which she acquired 319 shares of Colgate common stock at a price of $82.13 per share. After this transaction she beneficially owned 39,061 shares in a direct ownership form. The filing states the purchase reflects a portion of an annual cash retainer deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
John P. Bilbrey, a director of Colgate-Palmolive Company (CL), reported an acquisition on 10/01/2025 of 289 shares of the issuer's common stock at a price of $82.13 per share. Following the transaction, Mr. Bilbrey directly beneficially owns 36,658 shares and indirectly owns 4,719 shares through a trust. The filing states the reason for the acquisition: a portion of his annual cash retainer was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors, resulting in the issuance of common stock.
The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025. No derivative transactions, dispositions, or other changes are disclosed in this Form 4.
Jennifer Daniels, CLO and Secretary of Colgate-Palmolive Company (CL), reported insider dispositions on 09/12/2025 and 09/13/2025. The filings show withholding of 521 shares on 09/12/2025 at $83.28 per share and withholding of 900 shares on 09/13/2025 at $83.28 per share, reducing her direct beneficial ownership to 76,559 shares. In addition, she is shown as beneficially owning 1,813 shares indirectly held by the issuer's 401(k) plan trustee. The filer explains these dispositions were withholdings to satisfy tax liabilities arising from the vesting of restricted stock units under the companys incentive plan.